There is limited data available on healthcare resource utilization (HRU) associated with metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVES: To assess HRU in mCRPC patients during treatment. METHODS: Observational, retrospective, year-long study conducted in 47 centres specialised in prostate cancer (PC) in 6 countries: Belgium, France, Germany, Sweden, the Netherlands, and the United Kingdom. Patients with confirmed mCRPC diagnosis and documented disease progression were eligible. HRU data over the previous 2 years (or from mCRPC diagnosis onwards if <2 years) were collected from patients’ medical records by physicians. Interim results on 212 patients, of 699 included patients, are presented below. RESULTS: Mean age was 73.0 years. Mean time since PC diagnosis was 6.6 years. At diagnosis, 35.7% of patients had metastases and 79.7% had Gleason score ≥7. At inclusion, 33.8% of patients had never been treated with any prior chemotherapy, 35.3% had been treated with chemotherapy previously and 30.8% were currently undergoing chemotherapy. Mean time since failure on androgen-deprivation therapy was respectively 1.2, 1.6 and 1.5 years. Chemotherapy consisted principally of docetaxel (82.0%). Patients without prior chemotherapy presented lower rates of PC surgery (5.9%) than patients with past (11.3%) or ongoing chemotherapy (12.9%). Palliative radiotherapy was more frequent in patients with past chemotherapy (28.2%) than in patients without prior chemotherapy (19.1%) or with ongoing chemotherapy (14.5%). Higher hospitalisation rates were observed in patients with past (43.7%) or ongoing chemotherapy (43.5%) than in patients without prior chemotherapy (23.5%). Mean hospitalisation durations were roughly equivalent (respectively 6.1, 6.8 and 5.7 days). Emergency room visits were more frequent in patients with ongoing chemotherapy (14.5%) than in patients without prior chemotherapy (7.4%) or with past chemotherapy (9.9%). CONCLUSIONS: This study provides HRU information, which will be implemented into a cost analysis in order to highlight the determinants of  the economic burden of mCRPC patients.